{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:04:20Z","timestamp":1769216660223,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We investigated the long-term effectiveness, safety, and factors affecting Japanese Health Assessment Questionnaire (J-HAQ) improvement during abatacept treatment in Japanese rheumatoid arthritis (RA) patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Orencia\u00ae Registry in Geographically Assembled Multicenter Investigation (ORIGAMI) study is an ongoing observational study of biologic-na\u00efve RA patients with moderate disease activity treated with subcutaneous abatacept (125\u2009mg, once weekly). Patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) were extracted from the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) registry as a historical, weighted control group. The primary end point for this interim analysis was the proportion of patients with J-HAQ remission (score \u22640.5) at 3\u2009years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 279 abatacept-treated and 220 csDMARD-treated patients, J-HAQ remission was achieved at 3\u2009years in 40.5% [95% confidence interval (CI) 34.7\u201346.2%] and 28.9% (95% CI 9.9\u201347.8%), respectively. Age, RA duration &amp;lt;1\u2009year, baseline J-HAQ score, and Simplified Disease Activity Index remission at 6\u2009months were associated with 3-year J-HAQ remission in the abatacept group. Overall, 24\/298 patients (8.1%; safety analysis set) experienced serious adverse drug reactions with an incidence of 5.3 per 100 person-years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study confirmed the 3-year effectiveness and safety and revealed potential factors associated with J-HAQ remission in biologic-na\u00efve RA patients treated with abatacept in real-world clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae043","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T13:35:25Z","timestamp":1715348125000},"page":"17-26","source":"Crossref","is-referenced-by-count":1,"title":["Factors contributing to the improvement in Japanese Health Assessment Questionnaire after 3\u2009years of treatment with abatacept in biologic-na\u00efve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI)"],"prefix":"10.1093","volume":"35","author":[{"given":"Kenta","family":"Misaki","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Kita-Harima Medical Center , Hyogo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]},{"name":"Showa University Research Administration Center, Showa University , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminori","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, NHO Asahikawa Medical Center , Hokkaido,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Bayside Misato Medical Center , Kochi,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taio","family":"Naniwa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University , Aichi,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Oshikawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japanese Red Cross Kumamoto Hospital , Kumamoto,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamami","family":"Yoshitama","sequence":"additional","affiliation":[{"name":"Yoshitama Clinic for Rheumatic Diseases , Kagoshima,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Takakubo","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Surgery, Yamagata University Hospital , Yamagata,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Izumi Himawari Clinic , Miyagi,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinkichi","family":"Himeno","sequence":"additional","affiliation":[{"name":"Himeno Hospital , Fukuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuki","family":"Tsuritani","sequence":"additional","affiliation":[{"name":"Department of Immunology Medical, Bristol-Myers Squibb K.K. , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Medical Affairs, Ono Pharmaceutical Co., Ltd. , Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]},{"name":"Department of Rheumatology, Sanno Medical Center , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"2025020515453315500_R1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025020515453315500_R2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2025020515453315500_R4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.11465","article-title":"Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis","volume":"49","author":"Matsuda","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2025020515453315500_R5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00198-012-2080-0","article-title":"Risk factors associated with the occurrence of hip fracture in Japanese patients with rheumatoid arthritis: a prospective observational cohort study","volume":"24","author":"Furuya","year":"2013","journal-title":"Osteoporos Int"},{"key":"2025020515453315500_R6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/mr\/roac105","article-title":"Association between patient-reported outcomes and impairments in work and activity in patients with rheumatoid arthritis in clinical remission: a retrospective analysis using the IORRA database","volume":"33","author":"Sakai","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3109\/s10165-012-0816-5","article-title":"Functional disability can deteriorate despite suppression of disease activity in patients with rheumatoid arthritis: a large observational cohort study","volume":"23","author":"Seto","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00296-010-1671-3","article-title":"Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan","volume":"32","author":"Shidara","year":"2012","journal-title":"Rheumatol Int"},{"key":"2025020515453315500_R9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3899\/jrheum.110770","article-title":"The influence of individual joint impairment on functional disability in rheumatoid arthritis using a large observational database of Japanese patients","volume":"39","author":"Shidara","year":"2012","journal-title":"J Rheumatol"},{"key":"2025020515453315500_R10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/14397595.2016.1213490","article-title":"The minimally important difference for the Japanese version of the health assessment questionnaire in patients with rheumatoid arthritis in daily practice","volume":"27","author":"Shidara","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3899\/jrheum.160395","article-title":"Continual maintenance of remission defined by the ACR\/EULAR criteria in daily practice leads to better functional outcomes in patients with rheumatoid arthritis","volume":"44","author":"Shidara","year":"2017","journal-title":"J Rheumatol"},{"key":"2025020515453315500_R12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3109\/14397595.2015.1059983","article-title":"Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; analysis of the IORRA database","volume":"26","author":"Hoshi","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3109\/03009741003604542","article-title":"Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA","volume":"39","author":"Nakajima","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"2025020515453315500_R14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2025020515453315500_R15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025020515453315500_R16","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/mr\/roab090","article-title":"Effectiveness and safety of subcutaneous abatacept in biologic-na\u00efve RA patients at Week 52: a Japanese multicentre investigational study (ORIGAMI study)","volume":"32","author":"Tamura","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R17","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/mr\/roab050","article-title":"Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance","volume":"32","author":"Harigai","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","article-title":"A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options","volume":"30","author":"Yamanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R19","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025020515453315500_R20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40744-021-00412-x","article-title":"Post hoc analysis of the correlation between patient-reported outcomes and clinical response to repository corticotropin injection for persistently active rheumatoid arthritis","volume":"9","author":"Fleischmann","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025020515453315500_R21","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02590-z","article-title":"Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis","volume":"23","author":"Tanaka","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025020515453315500_R22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/mr\/road045","article-title":"Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-na\u00efve patients with rheumatoid arthritis: post-hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI)","volume":"34","author":"Misaki","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/mr\/roac032","article-title":"Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-na\u00efve patients with rheumatoid arthritis: post-hoc subgroup analysis of the ORIGAMI study","volume":"33","author":"Azuma","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R24","article-title":"Contribution of the factors to EuroQol 5 dimensions in rheumatoid arthritis patients achieving low disease activity\/remission with abatacept treatment: post hoc subgroup analyses of the Japanese real-world observational \u2018ORIGAMI\u2019 study","author":"Harigai","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R25","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"2025020515453315500_R26","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"2025020515453315500_R27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","article-title":"Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration","volume":"43","author":"Anderson","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2025020515453315500_R28","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1488-5","article-title":"Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting","volume":"20","author":"Alten","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025020515453315500_R29","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9062017","article-title":"Background glucocorticoid therapy has no impact on efficacy and safety of abatacept or adalimumab in patients with rheumatoid arthritis","volume":"9","author":"Degbo\u00e9","year":"2020","journal-title":"J Clin Med"},{"key":"2025020515453315500_R30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","article-title":"Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy","volume":"67","author":"Genovese","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2025020515453315500_R31","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.23397","article-title":"Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate","volume":"58","author":"Kremer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2025020515453315500_R32","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-15-14","article-title":"Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study","volume":"15","author":"N\u00fc\u00dflein","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"2025020515453315500_R33","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2025020515453315500_R34","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/mr\/roab029","article-title":"Efficacy and safety of abatacept in biologic-na\u00efve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R35","first-page":"494","article-title":"Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data","volume":"29","author":"Yazici","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2025020515453315500_R36","article-title":"Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial","volume":"24","author":"Bergman","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025020515453315500_R37","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3109\/14397595.2013.872862","article-title":"Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(\u00ae) as Biological Intensive Treatment for RA (ORBIT) study","volume":"24","author":"Tanaka","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R38","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/annrheumdis-2013-204178","article-title":"Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort","volume":"74","author":"Combe","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025020515453315500_R39","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-023-03176-7","article-title":"Ten-year radiographic and functional outcomes in rheumatoid arthritis patients in remission compared to patients in low disease activity","volume":"25","author":"Ruyssen-Witrand","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2025020515453315500_R40","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14397595.2016.1265726","article-title":"Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy","volume":"27","author":"Hirano","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R41","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025020515453315500_R42","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14397595.2016.1259715","article-title":"Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: a multi-center, prospective cohort study in Japan","volume":"27","author":"Yamazaki","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2025020515453315500_R43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194130","article-title":"Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis \u2013 the ANSWER cohort study","volume":"13","author":"Ebina","year":"2018","journal-title":"PLoS One"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae043\/58183594\/roae043.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/1\/17\/58183594\/roae043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/1\/17\/58183594\/roae043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T15:45:52Z","timestamp":1738770352000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/1\/17\/7668181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,5,10]]},"published-print":{"date-parts":[[2024,12,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae043","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,5,10]]}}}